Results 161 to 170 of about 14,494 (232)

Efficacy and tolerability of tenofovir alafenamide fumarate prophylaxis in HBV-infected individuals receiving chemo/immunosuppressive therapy. [PDF]

Hepatol Forum
Dilber F, Durak S, Unsal Y, Demir M, Yildirim AE, Ellik ZM, Mehdiyev S, Adanir H, Yapali S, Demirtas CO, Ucbilek E, Balaban Y, Ekmen N, Gokcan H, Koc ES, Dincer D, Sezgin O, Simsek H, Tozun N, Arslan M, Idilman R, Etik DO, Gokcen P, Ari D, Ozdil K, Akdogan M, Boyacioglu S.   +26 more
europepmc   +1 more source

Effect of alcohol exposure on the efficacy and safety of tenofovir alafenamide fumarate, a major medicine against human immunodeficiency virus. [PDF]

Biochem Pharmacol, 2022
Liu W, Yu S, Yan B.
europepmc   +1 more source

Early experience of dolutegravir pharmacokinetics in pregnancy: high maternal levels and significant foetal exposure with twice-daily dosing [PDF]

, 2016
Chaponda, Mas, Khoo, Saye, Lewis, Joseph M, Railton, Eimear, Riordan, Andrew   +4 more
core   +1 more source

P030: Renal and bone safety of tenofovir alafenamide versus tenofovir disoproxil fumarate

Journal of the International AIDS Society, 2015
Edwin DeJesus, Paul Sax, Michael Yin, Frank Post, Shinichi Oka, Ellen Koenig, Benoit Trottier, Jaime Andrade-Villanueva, Huyen Cao, Julie Ryu, Marshall Fordyce   +10 more
openaire   +1 more source

Virologic, immunologic, and metabolic outcomes and mortality in people with HIV on bictegravir/emtricitabine/tenofovir alafenamide fumarate versus dolutegravir-based antiretroviral therapies: a retrospective multicenter cohort study in China. [PDF]

Lancet Reg Health West Pac
Wu X, Ma P, Ruan L, Chen Y, Wang R, Song Y, Cai Y, Chen F, Zhang L, Fitzpatrick T, Li B, Wu G, Meng X, Fan S, Qiao Y, Gao Y, Hong Z, Zhang T, Zou M, Wang L, Fu Y, Su B, Zou J, Wang H, Zou H.   +24 more
europepmc   +1 more source

Efficacy and safety of tenofovir alafenamide fumarate in nucleoside analogue treatment-naïve patients with chronic hepatitis B. [PDF]

Exp Ther Med, 2021
Chen P, Wei W, Jin L, Kuai W, Li F, Liu H, Jiang B, Zhu Y.   +7 more
europepmc   +1 more source

Development and Validation of a Stability-Indicating RP-HPLC Method for the Simultaneous Estimation of Bictegravir, Emtricitabine, and Tenofovir Alafenamide Fumarate [PDF]

Turk J Pharm Sci, 2021
Attaluri T, Seru G, Varanasi SNM.
europepmc   +1 more source

Single dose topical inserts containing tenofovir alafenamide fumarate and elvitegravir provide pre- and post-exposure protection against vaginal SHIV infection in macaques. [PDF]

EBioMedicine, 2022
Dobard CW, Peet MM, Nishiura K, Holder A, Dinh C, Mitchell J, Khalil G, Pan Y, Singh ON, McCormick TJ, Agrahari V, Gupta P, Jonnalagadda S, Heneine W, Clark MR, García-Lerma JG, Doncel GF.   +16 more
europepmc   +1 more source

Preventive efficacy of a tenofovir alafenamide fumarate nanofluidic implant in SHIV-challenged nonhuman primates. [PDF]

Adv Ther (Weinh), 2021
Pons-Faudoa FP, Sizovs A, Shelton KA, Momin Z, Niles JA, Bushman LR, Xu J, Chua CYX, Nichols JE, Demaria S, Ittmann MM, Hawkins T, Rooney JF, Marzinke MA, Kimata JT, Anderson PL, Nehete PN, Arduino RC, Ferrari M, Sastry KJ, Grattoni A.   +20 more
europepmc   +1 more source

Tenofovir alafenamide fumarate therapy in subjects with positive HBV-DNA and normal levels of alanine transaminase: a study protocol for a randomised controlled trial. [PDF]

BMJ Open, 2021
Wang L, Wu L, Li X, Zhang Y, Lai J, Zhu X, Xie C, Peng L.   +7 more
europepmc   +1 more source